Basic Information
OncoResponse is leveraging our proprietary human antibody platform to discover new targets and identify fully human monoclonal antibodies that can be used as cancer treatments, expanding curative options to the vast majority of patients who do not respond to immunotherapy.
OncoResponse, Inc.
Seattle,Washington,United States of America
15~50 people
January 01, 2015
info@oncoresponseinc.com
Enterprise Profile
Industrial Sector
Technology
Concept
Application Scenarios